CEG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Constellation Energy Corp (CEG) is not a strong buy for a beginner, long-term investor at this time. While the company has shown strong revenue growth and exceeded Q4 expectations, the significant drop in net income and EPS, coupled with mixed analyst ratings and regulatory risks, suggest caution. The technical indicators and options data do not strongly support a buy decision, and there are no recent Intellectia Proprietary Trading Signals to suggest immediate action.
The MACD is positive and contracting, indicating a potential weakening of bullish momentum. RSI is in the neutral zone at 75.094, and moving averages are converging, showing no clear trend. The stock is trading above its pivot point of 313.88, with resistance levels at 330.96 and 341.511. Overall, the technical indicators suggest a neutral to slightly bullish trend but lack strong conviction.
Strong Q4 performance with revenue growth of 12.86% YoY and new power supply agreements following the Calpine acquisition. Positive developments in PJM reliability auctions and potential demand increases. Analysts like TD Cowen and Wells Fargo maintain Buy ratings with high price targets.
Significant YoY drops in net income (-49.30%) and EPS (-48.89%). Gross margin declined by 21.94%. Regulatory risks and potential market intervention disfavoring existing facilities. Mixed analyst ratings with some firms lowering price targets. Neutral sentiment from hedge funds and insiders.
In Q4 2025, revenue increased by 12.86% YoY to $6.07 billion, but net income dropped by 49.30% to $432 million. EPS also declined by 48.89% to $1.38, and gross margin fell to 36.78%, down 21.94%. While revenue growth is strong, profitability metrics have weakened significantly.
Analyst ratings are mixed. TD Cowen and Wells Fargo maintain Buy ratings with high price targets of $454 and $460, respectively, citing strong catalysts and opportunities. However, Mizuho and Citi have Neutral ratings with lower price targets of $330 and $348, citing concerns about regulatory risks and market intervention.
